Exploring the pan-cancer landscape of posttranscriptional regulation

被引:3
|
作者
Ghoshdastider, Umesh [1 ]
Sendoel, Ataman [1 ]
机构
[1] Univ Zurich, Inst Regenerat Med IREM, Wagistr 12, CH-8952 Schlieren, Switzerland
来源
CELL REPORTS | 2023年 / 42卷 / 10期
基金
瑞士国家科学基金会; 欧洲研究理事会;
关键词
INTEGRATED PROTEOGENOMIC CHARACTERIZATION; HUMAN COLON; INSIGHTS; REVEALS; MTOR;
D O I
10.1016/j.celrep.2023.113172
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Understanding the mechanisms underlying cancer gene expression is critical for precision oncology. Posttranscriptional regulation is a key determinant of protein abundance and cancer cell behavior. However, to what extent posttranscriptional regulatory mechanisms impact protein levels and cancer progression is an ongoing question. Here, we exploit cancer proteogenomics data to systematically compare mRNA-protein correlations across 14 different human cancer types. We identify two clusters of genes with particularly low mRNA-protein correlations across all cancer types, shed light on the role of posttranscriptional regulation of cancer driver genes and drug targets, and unveil a cohort of 55 mutations that alter systems-wide posttranscriptional regulation. Surprisingly, we find that decreased levels of posttranscriptional control in patients correlate with shorter overall survival across multiple cancer types, prompting further mechanistic studies into how posttranscriptional regulation affects patient outcomes. Our findings underscore the importance of a comprehensive understanding of the posttranscriptional regulatory landscape for predicting cancer progression.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] The pan-cancer pathological regulatory landscape
    Falco, Matias M.
    Bleda, Marta
    Carbonell-Caballero, Jose
    Dopazo, Joaquin
    SCIENTIFIC REPORTS, 2016, 6
  • [2] The pan-cancer pathological regulatory landscape
    Matias M. Falco
    Marta Bleda
    José Carbonell-Caballero
    Joaquín Dopazo
    Scientific Reports, 6
  • [3] Pan-cancer landscape of homologous recombination deficiency
    Nguyen, Luan
    Martens, John W. M.
    Van Hoeck, Arne
    Cuppen, Edwin
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [4] Pan-cancer landscape of homologous recombination deficiency
    Luan Nguyen
    John W. M. Martens
    Arne Van Hoeck
    Edwin Cuppen
    Nature Communications, 11
  • [5] Oncogenic Landscape of Somatic Mutations Perturbing Pan-Cancer lncRNA-ceRNA Regulation
    Zhang, Yuanfu
    Han, Peng
    Guo, Qiuyan
    Hao, Yangyang
    Qi, Yue
    Xin, Mengyu
    Zhang, Yafang
    Cui, Binbin
    Wang, Peng
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [6] The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis
    Wei, Zhiting
    Zhou, Chi
    Zhang, Zhanbing
    Guan, Ming
    Zhang, Chao
    Liu, Zhongmin
    Liu, Qi
    ISCIENCE, 2019, 21 : 249 - +
  • [7] Pan-cancer proteogenomics expands the landscape of therapeutic targets
    Savage, Sara R.
    Yi, Xinpei
    Lei, Jonathan T.
    Wen, Bo
    Zhao, Hongwei
    Liao, Yuxing
    Jaehnig, Eric J.
    Somes, Lauren K.
    Shafer, Paul W.
    Lee, Tobie D.
    Fu, Zile
    Dou, Yongchao
    Shi, Zhiao
    Gao, Daming
    Hoyos, Valentina
    Gao, Qiang
    Zhang, Bing
    CELL, 2024, 187 (16)
  • [8] Pan-cancer proteogenomics expands the landscape of therapeutic targets
    Lei, Jonathan T.
    Savage, Sara R.
    Yi, Xinpei
    Wen, Bo
    Zhao, Hongwei
    Somes, Lauren K.
    Shafer, Paul W.
    Dou, Yongchao
    Gao, Qiang
    Hoyos, Valentina
    Zhang, Bing
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Pan-Cancer Biomarkers Changing the Landscape of Molecular Testing
    Yao, Jinjuan
    Arcila, Maria E.
    Ladanyi, Marc
    Hechtman, Jaclyn F.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2021, 145 (06) : 692 - 698
  • [10] The pan-cancer, pan-biomarker landscape for precision immuno-oncology.
    McLeod, Howard L.
    Berglund, Anders E.
    Yao, Jiqiang
    Avedon, Melissa
    Teer, Jamie K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)